Routine Blood Glucose Monitoring Does Not Predict Onset of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes

Diabetes Care. 2024 Mar 1;47(3):e29-e30. doi: 10.2337/dc23-1964.
No abstract available

MeSH terms

  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Diabetes Mellitus, Type 1* / chemically induced
  • Diabetes Mellitus, Type 1* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors* / adverse effects
  • Nivolumab / adverse effects

Substances

  • Immune Checkpoint Inhibitors
  • Blood Glucose
  • Nivolumab